The most significant achievements in the drug therapy of oncourology diseases in 2020–2021
DOI: 10.32364/2587-6821-2021-5-8-545-547
V.A. Solodkiy, R.A. Pavlov, A.G. Dzidzaria, A.N. Riger, R.A. Gafanov
Russian Research Center of X-ray Radiology, Moscow, Russian Federation
Recent years have been marked by serious breakthroughs in the drug therapy of malignant neoplasms. The results of new successful studies are received almost constantly, which affect both clinical practice and the fate of patients. The studies in oncourology are also actively conducted: over the past 12 months, another batch of data from clinical studies has been obtained, in particular, comparing various combinations of chemotherapy drugs, the possibilities of combined targeted and immune therapy. The article deals with issues related to the treatment of metastatic renal cell carcinoma, urothelial cancer, the use of radiopharmaceuticals in the treatment of castration-resistant prostate cancer, as well as adjuvant therapy of urothelial cancer, which has not yet found an unambiguous solution. Phases II and III data of clinical trials in combination with the leading experts’ opinions should help to improve the approach to the treatment of oncourology disea ses, especially in the late stages.
Keywords: renal cell carcinoma, urothelial cancer, metastatic castration-resistant prostate cancer, immunotargeting therapy, chemotherapy, adverse events.
For citation: Solodkiy V.A., Pavlov R.A., Dzidzaria A.G. et al. The most significant achievements in the drug therapy of oncourology diseases in 2020–2021. Russian Medical Inquiry. 2021;5(8):545–547 (in Russ.). DOI: 10.32364/2587-6821-2021-5-8-545-547.
About the authors:
Vladimir A. Solodkiy — Academician of the Russian Academy of Sciences, Professor, Director of the Russian Research Center of X-ray Radiology; 86, Profsoyuznaya str., Moscow, 117997, Russian Federation; ORCID iD 0000-0002-1641-6452.
Andrey Yu. Pavlov — Dr. Sc. (Med.), Professor, Deputy Director for Scientific and Therapeutic Work, Russian Research Center of X-ray Radiology; 86, Profsoyuznaya str., Moscow, 117997, Russian Federation; ORCID iD 0000-0002-2905-7735.
Alexander G. Dzidzaria — C. Sc. (Med.), Head of the Department of Oncourology, Russian Research Center of X-ray Radiology; 86, Profsoyuznaya str., Moscow, 117997, Russian Federation; ORCID iD 0000-0001-5789-375X.
Alexandra N. Riger — Clinical Resident of the Russian Research Center of X-ray Radiology; 86, Profsoyuznaya str., Moscow, 117997, Russian Federation; ORCID iD 0000-0002-2076-2016.
Rustem A. Gafanov — C. Sc. (Med.), Senior Researcher of the Department of Oncourology, Russian Research Center of X-ray Radiology; 86, Profsoyuznaya str., Moscow, 117997, Russian Federation; ORCID iD 0000-0002-7592-0392.
Contact information: Rustem A. Gafanov, e-mail: docgra@mail.ru.
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interests.
Received 31.05.2021.
Revised 24.06.2021.
Accepted 19.07.2021.
2. Motzer R., Alekseev B., Rha S.-Y. et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. 2021;384:1289–1300. DOI: 10.1056/NEJMoa2035716.
3. Cella D., Choueiri T.K., Blum S.I. et al. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with first-line nivolumab plus cabozantinib versus sunitinib: The CheckMate 9ER trial. J Clin Oncol. 2021;39(6 suppl):285–285. DOI: 10.1200/JCO.2021.39.6_suppl.285.
4. Pal S.K., Tangen C., Thompson I.M. et al. Sunitinib versus cabozantinib, crizotinib, or savolitinib in metastatic papillary renal cell carcinoma: Results from the randomized phase II SWOG 1500 study. J Clin Oncol. 2021;39(6 suppl):270–270. DOI: 10.1200/JCO.2021.39.6_suppl.270.
5. Powles T., Rosenberg J.E., Sonpavde G. et al. Primary results of EV-301: A phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma. J Clin Oncol. 2021;39(6 suppl):393–393. DOI: 10.1200/JCO.2021.39.6_suppl.393.
6. Powles T., Se Hoon Park, Voog E. et al. Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis. J Clin Oncol. 2020;38(18 Suppl):LBA1. DOI: 10.1200/JCO.2020.38.18_suppl.LBA1.
7. Grivas P., Park S., Voog E. et al. 704MO Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone with 1L chemotherapy for advanced urothelial carcinoma: Subgroup analyses from JAVELIN Bladder 100. Ann Oncol. 2020;31(suppl 4):S555–S556.
8. Alva A., Csöszi T., Ozguroglu M. et al. LBA23 Pembrolizumab combined with chemotherapy (C) vs C alone as first-line therapy for advanced urothelial carcinoma: KEYNOTE-361. Ann Oncol. 2020;31(suppl 4):S1155.
9. Galsky M.D., Arija J.A.A., Bamias A. et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): A multicentre, randomised, placebo-controlled phase III trial. Lancet. 2020;395:1547–1557. DOI: 10.1016/S0140-6736(20)30230-0.
10. Bajorin D.F., Witjes J.A., Gschwend J. et al. First results from the phase 3 CheckMate 274 trial of adjuvant nivolumab vs placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma (MIUC). J Clin Oncol. 2021;39(suppl 6):391–391. DOI: 10.1200/JCO.2021.39.6_suppl.391.
11. Hussain M.H.A., Powles T., Albers P. et al. IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab versus observation in high-risk muscle-invasive urothelial carcinoma. J Clin Oncol. 2020;38(15 Suppl):5000–5000. DOI: 10.1200/JCO.2020.38.15_suppl.5000.
12. Pal S.K., Daneshmand S., Matin S.F. et al. PROOF 302: A randomized, double-blind, placebo-controlled, phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring FGFR3 alterations. J Clin Oncol. 2020;38(15 Suppl):TPS5095. DOI: 10.1200/JCO.2020.38.15_suppl.TPS5095.
13. Novartis: Novartis announces positive result of phase III study with radioligand therapy 177Lu-PSMA-617 in patients with advanced prostate cancer. (Electronic resource.) URL: https://www.novartis.com/news/media-releases/novartis-announces-positive-result-phase-iii-study-radioligand-therapy-177lu-psma-617-patients-advanced-prostate-cancer. (access date: 04.16.2021).
14. Hofman M.S., Emmett L., Sandhu S.K. et al. 177Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer progressing after docetaxel: Updated results including progression-free survival and patient-reported outcomes (TheraP ANZUP). J Clin Oncol. 2021;39(suppl 6):6–6. DOI: 10.1200/JCO.2021.39.6_suppl.6.
15. De Bono J., Mateo J., Fizazi K. et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382:2091–2102. DOI: 10.1056/NEJMoa1911440.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
